In the current study, we utilized PAFR-expressing cellular NSCLC models, pharmacological agents, and molecular biology approaches to determine the effects of miR-149 and PAFR on the growth, as well as the cytotoxic response, of erlotinib and gefitinib. The gene discussed is PTAFR; the disease is non-small cell lung carcinoma.